455 On Other Exchanges
455 is not on other exchanges.

tianda pharmaceuticals ltd (455) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TIANDA PHARMACEUTICALS LTD (455)

Related News

No related news articles were found.

tianda pharmaceuticals ltd (455) Related Businessweek News

No Related Businessweek News Found

tianda pharmaceuticals ltd (455) Details

Tianda Pharmaceuticals Limited, an investment holding company, engages in the research and development, production, and sale of pharmaceutical, biotechnology, and healthcare products. It offers cardio-cerebrovascular, pediatric, cold and respiratory system, anti-infective, and detoxification drugs, as well as complementary health care products comprising bone health, heart health, immune booster, nutritional oil, vitamin and mineral, women’s nutrition, wellbeing, and personal care products. The company also provides medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. It primarily operates in the People’s Republic of China, Hong Kong, and Australia. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. Tianda Pharmaceuticals Limited is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.

424 Employees
Last Reported Date: 12/22/16

tianda pharmaceuticals ltd (455) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

tianda pharmaceuticals ltd
Tianda Pharmaceuticals Limited Announces Management Changes

The board of directors of Tianda Pharmaceuticals Limited announced that Mr. SHI Shaobin has discontinued to act as the managing director of the company on 1 February 2017 and Mr. FANG Wen Quan has been appointed as the MD with effect from 1 February 2017; and Mr. SHI has been re-designated from an executive director to a non-executive director of the company with effect from 1 February 2017. Mr. FANG is currently the chairman of Tianda Group Limited. Mr. FANG had signed an appointment letter with the company for acting as an ED commencing from 1 April 2016, which will end on the date of 31 March 2018. Mr. SHI had been the MD of the company during the period from 3 August 2015 to 31 January 2017. Mr. SHI had held the chairman of Guangzhou Pearl River Piano Group Co. Ltd. Mr. SHI had signed an appointment letter with the company for acting as the NED commencing from 1 February 2017, which will end on the date of 31 January 2019 and is subject to retirement by rotation at least once every three years pursuant to the Articles of Association of the company.

Tianda Pharmaceuticals Limited Reports Unaudited Consolidated Earnings Results for the Six Months Ended 30 September 2016

Tianda Pharmaceuticals Limited reported unaudited consolidated earnings results for the six months ended 30 September 2016. For the period, revenue was HKD 93,853,493 against HKD 102,473,766 a year ago. Profit before tax was HKD 20,715,499 against HKD 9,788,277 a year ago. Profit for the period attributable to owners of the company was HKD 11,525,520 against HKD 2,793,354 a year ago. Basic earnings per share were 0.54 cents against 0.14 cents a year ago.

Tianda Pharmaceuticals Limited to Report First Half, 2017 Results on Nov 25, 2016

Tianda Pharmaceuticals Limited announced that they will report first half, 2017 results on Nov 25, 2016


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

455 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 455.
View Industry Companies

Industry Analysis


Industry Average

Valuation 455 Industry Range
Price/Earnings 51.1x
Price/Sales 4.2x
Price/Book 1.0x
Price/Cash Flow 51.1x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TIANDA PHARMACEUTICALS LTD, please visit www.tiandapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.